Jeremy Cole

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 590 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +6

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania et al. · New England Journal of Medicine · 2023 · 407 citations · Full text

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 168 citations · Full text

Asthma, Severe Eosinophilic Asthma, Allergy +10

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 127 citations · Full text

Asthma, Rheumatology, Allergy +9

Preemptive Oral Treatment With Sumatriptan During a Cluster Period

I. Monstad, Annette Krabbe, Giuseppe Micieli et al. · Headache The Journal of Head and Face Pain · 1995 · 89 citations